Since the concept of surface plasmon amplification by stimulated emission of radiation (SPASER) was proposed in 2003, great progresses have been made on two kinds of plasmonic nanolasers, namely SPASER device and SPASER nanoparticle. In comparison, SPASER nanoparticle, with ultra‐narrow emission line, small size, and good biocompatibility, is a kind of promising luminescent nanoprobe and has a bright application prospect in biomedical imaging and sensing. Hence, it is gradually becoming an attractive research hotspot in the world. However, as the research on SPASER nanoparticle is still in its infancy, there are still lots of problems to be solved before it is widely applied. In this paper, the latest research advances of SPASER nanoparticles and their biological applications are reviewed. Besides existing problems, challenges and opportunities of SPASER nanoparticles as next generation luminescent nanoprobes are discussed as well.

At present, there is an increasing focus on stents that have a biodegradable polymer coating, rather than a permanent polymer coating. This is due to the fact that following the implantation of a drug-eluting stent (DES) with a permanent polymer coating, the continued existence of the coating may result in a foreign body reaction and delayed re-endothelialization. The aim of the present study was to evaluate the safety and efficacy of a non-polymeric paclitaxel-eluting microporous (YINYI™) stent in real-life percutaneous coronary intervention (PCI) for patients with coronary artery disease (CAD). A total of 686 YINYI™ stents were implanted in 404 patients with CAD in a PCI procedure and outpatient follow-ups were performed 1, 6, 12 and 15 months subsequent to the PCI, respectively. The observation endpoints were major adverse cardiac events (MACEs), including cardiac death, non-fatal myocardial infarction (MI), restenosis, target lesion revascularization, stent thrombosis and recurrence of angina pectoris. The average follow-up time was 15 months. The results revealed that the cumulative incidences of MACEs were as follows: mortality, 0.99%; non-fatal MI, 0.74%; restenosis, 4.0%; and target lesion revascularization, 2.7%. The results at the short- and long-term clinical follow-ups indicated that YINYI™ stents are effective and safe for use in PCI for patients with CAD.